nach oben

Erschienen in:

04.07.2022 | Original Article

The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy

verfasst von: Natalia Zhukova, Rashida Orlova, Anna Malkova, Ekaterina Kaledina, Alexandra Demchenkova, Ruth Percik, Yehuda Shoenfeld

Erschienen in: Immunologic Research | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

At the moment, there are no approved predictive markers of immune adverse events (irAES) induced by immune checkpoint inhibitors (ICIs) and the treatment efficacy. The early stages of irAES have some similarities with adjuvant-induced autoimmune/pro-inflammatory syndrome (ASIA). This study aims to assess the predictive possibility of using the “ASIA questionnaire” in patients on immune checkpoint inhibitor therapy in comparison with determination of PD-L1 expression to predict the risk of irAES development and therapy efficacy. We examined patients (n = 91) being treated for solid tumors. The signs of ASIA were found in 74% (66/91), while ASIA syndrome was diagnosed in 54% of cases (49/91). No statistically significant difference in the frequency of ICI-dependent complication development regarding the presence of previous ASIA clinical manifestations, hereditary factors, sex, different trigger factors was found. Index based on combination of PD-L1 determination and ASIA index was created. With reference > 2.5 units, the disease control rate (DCR) could be predicted with sensitivity 100.0% and specificity 70.00%, p = 0.007. The study did not reveal the diagnostic value of ASIA questionnaire to assess the risk of adverse events; however, in early stages, the development of ASIA symptoms diagnosed with the questionnaire in complex with PD-L1 expression allowed to predict a treatment efficacy.

Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy [Internet]. Vol. 8, Frontiers in Pharmacology. Front Pharmacol. 2017.

Azoury S, Straughan D, Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets [Internet]. 2015;15(6):452–62.CrossRef

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review [Internet]. Vol. 54, European Journal of Cancer. Eur J Cancer; 2016. p. 139–48.

National Cancer Institute. Available online: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. No Title.

Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018 [Internet]. JAMA. 2018;320:1702–3.CrossRefPubMed

Weber JS, Dummer R, De Pril V, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer [Internet]. 2013;119(9):1675–82.CrossRef

Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and Activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med [Internet]. 2012;366(26):2455–65.CrossRef

Nishino M, Sholl LM, Hatabu H, Ramaiya NH, Hodi FS. Anti–PD-1–related pneumonitis during cancer immunotherapy. N Engl J Med [Internet]. 2015;373(3):288–90.CrossRef

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol [Internet]. 2018;4(12):1721–8.CrossRef

10.

Jiang Y, Zhang N, Pang H, Gao X, Zhang H. Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis. Ther Clin Risk Manag [Internet]. 2019;15:293–302.CrossRef

11.

Hoefsmit EP, Rozeman EA, Haanen JBAG, Blank CU. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open [Internet]. 2019;4(4).

12.

Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitorsJournal for ImmunoTherapy of. Cancer. 2019;7:306. https://doi.org/10.1186/s40425-019-0805-8.CrossRef

13.

Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis [published correction appears in. JAMA Oncol. 2018;4(12):1792–1728. https://doi.org/10.1001/jamaoncol.2018.3923.CrossRef

14.

Liu J, Blake SJ, Harjunpaa H, et al. Assessing immune-related adverse events of efficacious. Combination immunotherapies in preclinical models of cancer. Cancer Res. 2016;76(18):5288–301.CrossRefPubMed

15.

Xu Y, Wan B, Chen X, Zhan P, Zhao Y, Zhang T, et al. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl Lung Cancer Res. 2019;8(4):413–28.CrossRefPubMedPubMedCentral

16.

Duruisseaux M, Rouquette I, Adam J, Cortot A, Cazes A, Gibault L, et al. Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers. Ann Pathol [Internet]. 2017;37(1):61–78. https://doi.org/10.1016/j.annpat.2016.12.009.CrossRef

17.

Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: An analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.CrossRefPubMedPubMedCentral

18.

Aguiar PN Jr, Santoro I, Tadokoro H, Lopes G, Filardi BA, Barreto CMN, et al. 3122 The role of PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: A network meta-analysis. Eur J Cancer. 2015;8(4):479–8.

19.

Shoenfeld Y, Agmon-Levin N. “ASIA” - Autoimmune/inflammatory syndrome induced by adjuvants [Internet]. J Autoimmun. 2011;36:4–8.CrossRefPubMed

20.

Watad A, Quaresma M, Bragazzi NL, Cervera R, Tervaert JWC, Amital H, et al. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld’s syndrome: Descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol [Internet]. 2018;37(2):483–93.CrossRef

21.

Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus [Internet]. 2009;18(13):1217–25.CrossRef

22.

De Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol Res [Internet]. 2019;7(1):6–11.CrossRef

23.

Arango MT, Perricone C, Kivity S, Cipriano E, Ceccarelli F, Valesini G, et al. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. Immunol Res [Internet]. 2017;65(1):82–98.CrossRef

24.

Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: Who might be at risk? [Internet]. Pharmacol Res. 2015;92:18–22.CrossRefPubMed

25.

Goren I, Segal G, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvant (ASIA) evolution after silicone implants. Who is at risk? Clin Rheumatol [Internet]. 2015;34(10):1661–6.CrossRef

26.

Scanzi F, Andreoli L, Martinelli M, Taraborelli M, Cavazzana I, Carabellese N, et al. Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures. Immunol Res [Internet]. 2017;65(1):150–6.CrossRef

27.

Shoenfeld Y, Agmon-Levin N. Autoimmune or auto-inflammatory syndromes induced by adjuvants. Harefuah. 2012;151:9–11.PubMed

28.

Teuber SS, Rowley MJ, Yoshida SH, Ansari AA, Gershwin ME. Anti-collagen autoantibodies are found in women with silicone breast implants. J Autoimmun [Internet]. 1993;6(3):367–77.CrossRef

29.

Sun HH, Sachanandani NS, Jordan B, Myckatyn TM. Sarcoidosis of the breasts following silicone implant placement [Internet]. Plast Reconstr Surg. 2013;131.

30.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. In: JAMA Oncology [Internet]. JAMA Oncol. 2016;234–40.

31.

Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al. Profiling preexisting antibodies in patients treated with antI–PD-1 therapy for advanced non–small cell lung cancer. JAMA Oncol [Internet]. 2019;5(3):376.CrossRef

32.

Geier DA, Geier MR. A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol [Internet]. 2015;34(7):1225–31.CrossRef

33.

Watad A, Quaresma M, Brown S, Tervaert JWC, Rodríguez-Pint I, Cervera R, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome) – An update: [Internet]. 2017;26(7):675–81 https://doi.org/10.1177/0961203316686406.

34.

Valenta R, Mittermann I, Werfel T, Garn H, Renz H. Linking allergy to autoimmune disease. Trends Immunol [Internet]. 2009;30(3):109–16.CrossRef

35.

Maijers MC, de Blok CJM, Niessen FB, van der Veldt AAM, Ritt MJPF, Winters HAH, Kramer MH, Nanayakkara PW. Women with silicone breast implants and unexplained systemic symptoms: A descriptive cohort study. Neth J Med. 2013;71:534–40.PubMed

36.

Watad A, Bragazzi NL, McGonagle D, Adawi M, Bridgewood C, Damiani G, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. Clin Immunol [Internet]. 2019;203:1–8.CrossRef

37.

Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, et al. Estrogens and autoimmune diseases. In: Annals of the New York Academy of Sciences [Internet]. Blackwell Publishing Inc.; 2006. p. 538–47.

38.

Invernizzi P, Pasini S, Selmi C, Gershwin ME, Podda M. Female predominance and X chromosome defects in autoimmune diseases [Internet]. J Autoimmun. 2009;33:12–6.CrossRefPubMed

39.

A, Desai-Mehta L, L R-G, R D. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest [Internet]. 1996;97(9):2063.

40.

Dorak M, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet [Internet]. 2012;3(NOV):1–11.

41.

Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls [Internet]. Curr Oncol Rep. 2020;22.

42.

McGinnis GJ, Raber J. CNS side effects of immune checkpoint inhibitors: Preclinical models, genetics and multimodality therapy [Internet]. Immunotherapy. 2017;9:929–42.CrossRefPubMedPubMedCentral

43.

Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis [Internet]. BMJ (Online). 2018;360

44.

Hiroki U, Eriko M, Yuka O, Eri T, Takahiro K, Yuhei H, Nao Y, Katsuyuki F, Chigusa S, Nobuyuki Y. MO3–10–3-sustained fever associated with immune checkpoint inhibitors may be a poor prognostic factor. Ann Oncol. 2019;30:vi115.CrossRef

45.

Osamu K, Kohei F, Misato O, Kanna H, Keiko T, Masayuki H, Koichi N, Satoru S, Tadashi M. Impact of nivolumab-induced fever on the treatment effect: A retrospective study. Eur Respir J. 2019;54:PA368.

46.

Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer [Internet]. 2019;107:8–14.CrossRef

Titel: The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy
verfasst von: Natalia Zhukova
Rashida Orlova
Anna Malkova
Ekaterina Kaledina
Alexandra Demchenkova
Ruth Percik
Yehuda Shoenfeld
Publikationsdatum: 04.07.2022
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 6/2022
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-022-09304-w

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy

Abstract

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review

Hyper IgM in tricho-hepato-enteric syndrome due to TTC37 mutation

Long-term use of broad-spectrum antibiotics affects Ly6Chi monocyte recruitment and IL-17A and IL-22 production through the gut microbiota in tumor-bearing mice treated with chemotherapy

Correction to: Human placental extract attenuates neurological symptoms in the experimental autoimmune encephalomyelitis model of multiple sclerosis-a putative approach in MS disease?

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis

Somatic hypermutation defects in two adult hyper immunoglobulin M patients

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update HNO